$630 Million

Tigenix

Sell-side

Exclusive Financial Advisor, January 2018

Tigenix
Acquisition by Takeda Pharmaceutical Company Limited

TiGenix is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, expanded stem cells. The Company’s lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas. In December 2017, the CHMP of the EMA adopted a positive opinion recommending a marketing authorization for Cx601 in this indication, the first allogeneic stem cell therapy to achieve this. Further, a global Phase III trial intended to support a future U.S. BLA has also been initiated. This transaction represents a natural extension of the existing July 2016 exclusive ex-U.S. license, development and commercialization agreement for Cx601 between Takeda and the Company.

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >